Get the Stockscreener App
1.35
6.30%
0.08
After Hours:
1.37
0.02
+1.48%
Mainz Biomed N V stock is traded at $1.35, with a volume of 1.39M.
It is up +6.30% in the last 24 hours and up +16.38% over the past month.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
See More
Previous Close:
$1.27
Open:
$1.45
24h Volume:
1.39M
Relative Volume:
2.51
Market Cap:
$12.23M
Revenue:
$895.50K
Net Income/Loss:
$-26.30M
P/E Ratio:
-0.0206
EPS:
-65.5728
Net Cash Flow:
$-23.84M
1W Performance:
+16.38%
1M Performance:
+16.38%
6M Performance:
-5.59%
1Y Performance:
-73.37%
1-Day Range:
$1.30
$1.50
1-Week Range:
$1.08
$1.50
52-Week Range:
$0.92
$8.20
Mainz Biomed N V Stock (MYNZ) Company Profile
Name
Mainz Biomed N V
Sector
Industry
Phone
-
Address
-
Compare MYNZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYNZ
Mainz Biomed N V
|
1.35 | 11.51M | 895.50K | -26.30M | -23.84M | -65.57 |
|
TMO
Thermo Fisher Scientific Inc
|
620.72 | 229.63B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
236.59 | 166.25B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
706.83 | 54.48B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
147.60 | 40.52B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
240.53 | 39.95B | 15.90B | 1.28B | 2.21B | 7.2842 |
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-25 | Initiated | Maxim Group | Buy |
| Nov-25-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-21-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-21-22 | Initiated | H.C. Wainwright | Buy |
Mainz Biomed N V Stock (MYNZ) Latest News
Mainz Biomed Provides Review of 2025 Highlights - GlobeNewswire
Earnings Risk: Why analysts upgrade Pony AI Inc Depositary Receipt stock2025 Short Interest & Weekly Consistent Profit Watchlists - moha.gov.vn
Is Mainz Biomed NV a good long term investmentBullish Engulfing Patterns & Insights From Wall Street Professionals - earlytimes.in
Form 424B5 MAINZ BIOMED N.V. - StreetInsider
Mainz Biomed (NASDAQ:MYNZ) Upgraded by Wall Street Zen to Hold Rating - Defense World
Mainz Biomed (NASDAQ:MYNZ) Stock Price Up 2.7% – Still a Buy? - Defense World
Why retail investors favor Mainz Biomed N.V. stockSwing Trade & Fast Gaining Stock Strategy Reports - Улправда
Why Mainz Biomed N.V. (4TO) stock is a strong buy callJuly 2025 Trade Ideas & AI Driven Price Predictions - Улправда
How strong is Mainz Biomed N.V. stock revenue growthWeekly Trend Summary & Fast Gain Swing Alerts - Улправда
Why Mainz Biomed N.V. stock remains undervalued2025 EndofYear Setup & Risk Controlled Stock Pick Alerts - Улправда
Will Mainz Biomed N.V. stock reach all time highs in 20252025 Year in Review & Weekly Watchlist of Top Performers - Улправда
How Mainz Biomed N.V. stock reacts to inflationary pressuresJuly 2025 Sector Moves & Verified Momentum Watchlists - ulpravda.ru
Is Mainz Biomed N.V. stock a buy for dividend growthJuly 2025 Movers & Reliable Intraday Trade Alerts - Улправда
2 Small-Cap Biotechs That Could Reward Patient Investors - Investing.com
2 Small-Cap Biotechs That Could Reward Patient Investors - sharewise.com
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Is Mainz Biomed N.V. stock positioned for long term growthJuly 2025 News Drivers & AI Forecast Swing Trade Picks - Newser
Mainz Biomed (Nasdaq: MYNZ) targets $150M shelf to advance cancer diagnostics - Stock Titan
Why Mainz Biomed N.V. (4TO) stock attracts wealthy investorsWeekly Market Outlook & Stock Portfolio Risk Control - Newser
Can Mainz Biomed N.V. (4TO) stock sustain free cash flow2025 Top Gainers & Fast Moving Stock Trade Plans - Newser
Is Mainz Biomed N.V. (4TO) stock expanding market penetrationJuly 2025 News Drivers & AI Forecast Swing Trade Picks - Newser
DoctorBox Adds Mainz Biomed's ColoAlert to Its Portfolio - marketscreener.com
Why Mainz Biomed N.V. (4TO) stock is favored by hedge fundsProduct Launch & Weekly High Conviction Ideas - Newser
Mainz Biomed (MYNZ) Stock Analysis Report | Financials & Insights - Benzinga
DoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its Portfolio - GlobeNewswire
DoctorBox Adds Mainz Biomed’s ColoAlert® to Its Portfolio - TradingView — Track All Markets
Weekly Trades: Why hedge funds are buying Mainz Biomed N.V. stockJobs Report & Reliable Price Breakout Alerts - moha.gov.vn
Mainz Biomed N.V (MYNZ) looking to reclaim success with recent performance - Setenews
Mainz Biomed launches up to $2.6M at-the-market stock sale - Stock Titan
Mainz Biomed (NASDAQ:MYNZ) Shares Down 5.8% – What’s Next? - Defense World
Will Mainz Biomed N.V. stock see insider buyingJuly 2025 Closing Moves & Daily Profit Maximizing Trade Tips - newser.com
Is Mainz Biomed N.V. stock positioned well for digital economy2025 Bull vs Bear & Reliable Price Breakout Signals - newser.com
Is Mainz Biomed N.V. (4TO) stock attractive for dividend growth - newser.com
What’s the recovery path for long term holders of Mainz Biomed N.V.Earnings Growth Report & Stepwise Swing Trade Plans - newser.com
Can Mainz Biomed N.V. stock continue upward trend2025 Biggest Moves & Trade Opportunity Analysis Reports - newser.com
What margin trends mean for Mainz Biomed N.V. stockJuly 2025 Reactions & Breakout Confirmation Trade Signals - newser.com
Is a relief rally coming for Mainz Biomed N.V. holdersInflation Watch & Verified Technical Signals - newser.com
Will Mainz Biomed N.V. outperform the marketBond Market & Short-Term Trading Opportunity Alerts - newser.com
How Mainz Biomed N.V. (4TO) stock performs in easing cycles - newser.com
Mainz Biomed N V Stock (MYNZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):